The European drug authority recommends refusal of marketing authorization due to evidence gaps in quality and efficacy.

Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the ...

Q2 2025 Earnings Call Transcript July 30, 2025 Anika Therapeutics, Inc. reports earnings inline with expectations. Reported ...

OvertureTi Knee Resurfacing System implants are designed specifically as an alternative when biological repair options are not viable for treating focal cartilage lesions.

Recently, a research team from Chongqing Medical University, led by Prof. Wei Huang, Dr. Wei Bao, and Dr. Yiting Lei, has successfully developed a novel engineered extracellular matrix (eECM) to ...

Non-GAAP adjusted EBITDA for the quarter ended June 30, 2025 was $13.4 million, or 21% of net revenue, compared to $6.3 million, or 12% of net revenue, for the second quarter of 2024. A table ...

Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million ...

A record ten early-stage TU/e researchers have been awarded a Veni grant from the Dutch Research Council (NWO). The NWO Veni grants are dedicated to ...

Anika Therapeutics' (NASDAQ:ANIK) stock falls as the company's cartilage repair product Hyalofast misses key trial endpoints ...

Shares of Anika Therapeutics hit a 52-week low after it said its Hyalofast cartilage-repair product didn't meet its co-primary endpoints in a Phase III study. The stock was recently down 24% to $8.43 ...